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a b s t r a c t  
Background: Acute myeloid leukemia (AML) remains one of the most lethal, rarely cured cancers, despite decades 
of active development of AML therapeutics. Currently, the 5-year survival of AML patients is about 30% and for 
elderly patients, the rate drops to b10%. About 30% of AML patients harbor an activating mutation in the tyrosine 
kinase domain (TKD) of Fms-Like Tyrosine kinase 3 (FLT3) or a FLT3 internal tandem duplication (FLT3-ITD). In-
hibitors of FLT3, such as Rydapt that was recently approved by the FDA, have shown good initial response but pa-
tients often relapse due to secondary mutations in the FLT3 TKD, like D835Y and F691 L mutations. 
Methods: Alkynyl aminoisoquinoline and naphthyridine compounds were synthesized via Sonogashira coupling. 
The compounds were evaluated for their in vitro and in vivo effects on leukemia growth. 
Findings: The compounds inhibited FLT3 kinase activity at low nanomolar concentrations. The lead compound, 
HSN431, also inhibited Src kinase activity. The compounds potently inhibited the viability of MV4–11 and 
MOLM-14 AML cells with IC50 values b1 nM. Furthermore, the viability of drug-resistant AML cells harboring 
the D835Y and F691 L mutations were potently inhibited. In vivo efficacy studies in mice demonstrated that 
the compounds could drastically reduce AML proliferation in mice. 
Interpretation: Compounds that inhibit FLT3 and downstream targets like Src (for example HSN431) are good 
leads for development as anti-AML agents. 
Fund: Purdue University, Purdue Institute for Drug Discovery (PIDD), Purdue University Center for Cancer Re-
search, Elks Foundation and NIH P30 CA023168. 
© 2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http:// 
creativecommons.org/licenses/by/4.0/). 
1. Introduction 
Acute myeloid leukemia (AML) is a devastating disease, which still 
remains difficult to treat despite massive efforts by drug companies 
and academia to find durable cures [1]. The five-year survival rate for 
AML hovers around 30% and for elderly patients over 65 years, the 
five-year survival rate is unfortunately low (b10%) [2–4]. It is hoped 
that the survival rate for AML will soon improve due to the introduction 
of newer and more potent FLT3 inhibitors and advances made in alloge-
neic bone marrow transplantation. AML is a heterogenous disorder with 
an array of mutations that contribute differentially to prognosis [5]. 
About 30% of AML patients harbor a mutation in the Fms-Like Tyrosine 
Kinase 3 (FLT3), which makes the leukemia more aggressive [6,7]. Inter-
nal tandem duplication (ITD) in the juxtamembrane domain as well as 
tyrosine kinase domain (TKD) mutations, like those at residues D835 
and F691, constitute FLT3 activating mutations [8–10]. When these mu-
tations are present, FLT3 signaling bypasses the requirement of the FLT3 
ligand for activation and hence becomes constitutively activated. 
Midostaurin (Rydapt), a FLT3 tyrosine kinase inhibitor (TKI), was 
approved in 2017 [11,12] and other FLT3 TKIs are being evaluated in 
clinical trials [13]. Midostaurin is not effective as a single agent and it 
is administered in combination with chemotherapy [11,12]. The 
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Research in context 
Evidence before this study 
FLT3 is a druggable target for about 30% of AML patients who 
harbor mutated FLT3 (ITD or TKD). A handful of FLT3 inhibitors 
evaluated in the clinic show good initial treatment response but 
patients ultimately relapse due to secondary mutations such as 
D835Y and F691 L, and other oncogenic activations. Hence ther-
apeutic agents capable of inhibiting drug-resistantAML are 
desirable. 
Added value of this study 
In this study, we presented alkynyl aminoisoquinoline and 
naphthyridine compounds as novel inhibitors of FLT3 kinase activ-
ity as well as downstream kinases such as Src/Raf. Importantly, 
the compounds potently inhibited the growth of drug-
resistantAML harboring the commonly observed D835Y and 
F691 L secondary mutations. The reported compounds are also 
efficacious in vivo (human AML xenograft models). 
Implications of all the available evidence 
This study provides new chemical entities that could be translated 
into therapeutics for relapsed AML patients who fail first/s gener-
ation FLT3 inhibitors, which are not very active against AML cells 
harboring D835 or F691 mutations. 
majority of the FLT3 inhibitors, which have been or are being evaluated 
in clinical trials show initial response, but patients often relapse with 
various FLT3 mutations (including secondary FLT3 mutations) and 
complete remission of AML is challenging [8,9,14–17]. FLT3 D835Y/V 
[18] and  F691  L  [17] are common mutations, which often emerge during 
treatment and are resistant to many FLT3 TKIs. New-generation FLT3 in-
hibitors that could be used as a mono therapy and/or exhibiting poten-
cies against mutated FLT3 (such as D835Y/V or F691 L) could improve 
AML survival rates. 
Several kinases, which are downstream of FLT3, collaborate with 
constitutively active FLT3 (FLT3-ITD or FLT3 with mutation in the kinase 
domain, particularly the D835 or F691 mutations), to exacerbate AML 
[19–22]. Src-family kinases play pivotal roles in microenvironment-
induced resistance to FLT3 inhibition [23]. Therefore, dual inhibitors of 
FLT3-Src-family kinases could be effective in overcoming drug resis-
tance. We recently reported that novel dual FLT3-Src-family kinase in-
hibitors (see Fig. 1) that contain alkynyl aminoisoquinoline moiety 
potently inhibited FLT3-ITD harboring AML cell lines, such as MV4–11 
and MOLM-14, with single digit nanomolar or even sub-nanomolar 
half maximal inhibitory concentration (IC50) values in vitro [24]. The 
impressive in vitro efficacies of the alkynyl aminoisoquinoline and 
alkynyl aminonaphthyridine compounds against AML cell lines harbor-
ing FLT3-ITD prompted us to conduct an extensive structure-activity re-
lationship (SAR) studies and to evaluate the efficacy of these 
compounds in mice. Here we present the SAR and corresponding effica-
cies of the second-generation alkynyl aminoisoquinoline and alkynyl 
aminonaphthyridine compounds. 
2. Materials and methods 
2.1. Chemicals, reagents and cell culture 
Midostaurin was purchased from Sigma (St. Louis, MO, USA), 
crenolanib, quizartinib and ponatinib were purchased from Adooq 
Bioscience (Irvine, CA, USA). MV4–11 cell line was a kind gift from Dr. 
Mark Levis (Johns Hopkins University). MOLM-14 (FLT3-ITD, D835Y) 
and MOLM-14 (FLT3-ITD, F691 L) [25] were kind gifts from Dr. Neil 
Shah (UCSF). The cells were routinely maintained in Roswell Park Me-
morial Institute (RPMI) 1640 medium supplemented with 10% fetal bo-
vine serum at 37 °C with 5% CO2. 
2.2. Analysis of antiproliferative activities 
Cells were seeded into 96-well tissue culture-treated plates at 2.0 
× 104 cells/mL for up to 24 h. DMSO stock solutions of compounds 
were serially diluted first in DMSO and subsequently into RPMI before 
being added to the cell cultures in triplicates, with 10 μM being the 
highest tested concentration. The plates were incubated for 72 h as 
above. The CellTitre-Blue assay (Promega, Madison WI) was then 
added to the cultures and incubated a further 4 h before the fluores-
cence measured following the manufacturers recommendations. The 
fluorescence data from compounds were normalized to that DMSO 
and the resulting data fitted to a non-linear regression equation to ob-
tain IC50 using GraphPad Prism 5.0 Software (La Jolla, CA, USA). 
To determine the effect of HSN431 on actual leukemia cell counts, 
MV4–11 cells were seeded into 96 well plates as above and treated 
with either DMSO vehicle, or HSN431 at the following concentrations: 
0.1 nM, 0.2 nM, 0.5 nM, 1 nM, 2 nM, 5 nM, and 10 nM. Cells were incu-
bated for 72 h, and then counted using trypan blue exclusion on the 
Countess automated cell counter (Life Technologies, Carlsbad, CA). Cell 
counts were performed in triplicates, and the averages, standard devia-
tions and t-test statistical analyses were graphed using GraphPad Prism 
software (GraphPad, La Jolla, CA). 
2.3. In vitro kinase assay 
Cell-free kinase activity assays were performed at Reaction Biology 
Corporation. Briefly, kinases were incubated with substrates, 100 μM 
ATP and a 3-fold serial dilution of compounds starting at 1 μM. DMSO 
was used as control. For single-dose inhibition of FLT3-ITD and Src ki-
nase activity, compounds were tested at 500 nM. Experiments were 
performed in duplicates. The concentrations of kinases and substrates 
used in the assays are indicated on Table S1. Kinase activity was quanti-
fied using the ADP-Glo™ Kinase Assay System (Promega, Madison, WI) 
following the manufacturer's recommendations. 
2.4. In vivo efficacy studies 
The in vivo efficacy of compounds was assessed in an orthotopic 
human AML model in NSG (NOD scid gamma, NOD-scid IL2Rgnull) 
mice that were bred at University of Maryland Baltimore (mating 
pairs acquired from Jackson Laboratories; Maine). Female NSG or NRG 
(NOD-Rag1null IL2rgnull, NOD rag gammaRnull, bred at Purdue Univer-
sity) mice (6–8 weeks old) were injected with 1 × 106 MV4–11-luc 
cells, a gift from Dr. Sharyn Baker (Ohio State University) via intrave-
nous injection into the lateral tail vein of restrained mice. Three days 
later, engraftment was assessed by imaging on a Xenogen IVIS-2 Imag-
ing System (Alameda) after an intraperitoneal (IP) injection of 
150 mg/kg luciferin. Mice were sorted into four or five groups (n = 5)  
so that mean intensity (i.e., disease burden) was equal. Dosing started 
on day of sorting. Compounds were dissolved in 85% PBS (pH 7.4) buffer 
containing 10% DMSO and 5% Cremophore. The vehicle (buffer without 
compounds) was used as control. Mice were injected 3 to 5 days per 
week via IP injection. Mice were weighed on day of dosing and imaged 
once per week. The endpoint of each study was survival (mice were eu-
thanized via AVMA-approved methods when they lost N20% of body 
weight or displayed hind limb paralysis). All mice were housed in a 
12-h light/dark cycle with access to food and water ad libitum. Studies  
were performed with Institutional Animal Care and Use Committee 
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Fig. 1. Dual FLT3/Src-kinase inhibitors reported by Larocque et al. [24]. 
2.5. Western blot analysis 
MV4–11 cultures were treated with 2 nM and 10 nM of com-
pounds for 6 h and 48 h. Total protein extraction, gel separation, 
transfer and imaging of blots were performed as previously de-
scribed [26]. The following primary antibodies from Cell Signaling 
Technologies (MA, USA) were used: Phospho-p70S6K (cat. no. 
9205, RRID: AB_330944), p70S6K (cat. no. 9202, RRID: AB_331676), 
Phospho-p38 (cat. no. 9211, RRID: AB_331641), p38 (cat. no. 9212, 
RRID: AB_330713), c-Myc (cat. no. 9402, RRID: AB_2151827), 
Phospho-FLT3 (cat. no. 3461, RRID: AB_331060), FLT3 (cat. no. 
3462, RRID: AB_10693420), Phospho-STAT5 (cat. no. 9359, RRID: 
AB_823649), STAT5 (cat. no. 9363, RRID: AB_2196923), Phospho-
ERK (cat. no. 9101, RRID: AB_331646), ERK (cat. no. 4695, RRID: 
AB_390779), Phospho-AKT (cat. no. 9271), AKT (cat. no. 9272, 
RRID: AB_329825), Phospho-Src (cat. no. 2101, RRID: AB_331697), 
Src (cat. no. 2110, RRID: AB_2106058), Phospho-STAT3 (cat. no. 
9145, RRID: AB_2491009), STAT3 (cat. no. 12640, RRID: AB_ 
2629499). Mouse anti-β-Actin antibody was purchased from Sigma 
(MO, USA). A horseradish peroxidase-conjugated anti-rabbit or 
anti-mouse antibody (Cell Signaling Technologies) was used as sec-
ondary antibody. Scanned images were analyzed using image J 
software. 
2.6. Cell cycle analysis and apoptosis 
Cells seeded into T-25 flasks at a density of 8.0 × 104 cells/mL and in-
cubated overnight at 37 °C with 5% CO2. Each treatment was performed 
in triplicates, with three flasks per treatment each with enough volume 
for both assays at the applicable time points. Following the overnight in-
cubation, cells were treated with either DMSO or different concentra-
tions of HSN431 (as indicated) in triplicates, mixed well and 
incubated. At each time point (24 and 48 h), aliquots of 1.5 mL of cells 
were collected from each flask and placed into labeled FACS tubes (for 
Annexin V apoptosis) or labeled 15 cc conical tubes (for cell cycle) and 
centrifuged at 300 × g for 5 min. Cells were washed twice with 1× PBS. 
For cell cycle, cell pellets were resuspended in 0.5 mL PBS in 15 cc 
conical tubes and fixed with 4.5 mL of 70% ethanol. Fixed cells were 
stored at −20 °C until analysis with the Propidium Iodide (PI) Flow Cy-
tometry Kit (cat. no. ab139418, Abcam, Cambridge, MA, USA). Samples 
were analyzed in duplicates on a FACSCanto II flow cytometer (BD Bio-
science, San Jose, CA, USA) and cell cycle distribution was analyzed 
using the Watson algorithm analysis in FlowJo software (Flowjo, LLC, 
Ashland, OR). 
For Annexin V apoptosis, cell pellets were resuspended in 100 μL of  
1× assay buffer and the binding of Annexin V and PI were measured 
by staining cells following the BD Pharmingen™ FITC Annexin V Apo-
ptosis Detection Kit I (cat. no. 556547, BD Biosciences, San Jose, CA, 
USA) recommendations. Flow cytometry was performed on a a 
FACSCanto II flow cytometer (BD Bioscience, San Jose, CA, USA) and 
data analyzed using the FlowJo software (Flowjo, LLC, Ashland, OR). 
2.7. Statistical analysis 
Non-linear regression analysis of the cell-free in vitro kinase activity 
dose-response data were performed using GraphPad Prism 5.0 Software 
(GraphPad, La Jolla, CA, USA). Photon intensity on whole body and ani-
mal survival data were analyzed by students t-test (paired; two tailed) 
in GraphPad Prism 5.0 Software (CA, USA). Significant differences have 
been indicated as * (P ≤ .05), ** (P ≤ .01) or *** (P ≤ .001) according to the 
level of significance. 
3. Results 
3.1. Second generation compounds inhibit FLT3/Src kinase activity 
For the expanded SAR study, additional nitrogens were incorporated 
into rings A and B (see Fig. 2) of  the  first-generation compounds 
HSN286, HSN334 and HSN356 to improve aqueous solubility (lower 
LogP). In addition to the water-solubilizing effects of basic nitrogens, it 
has also been well documented that the introduction of the so-called 
“essential nitrogen” or nitrile moieties into drugs improves target en-
gagement [27,28]. Fluorine has also been deemed a “magic” moiety 
that when incorporated into drugs could improve the potency as well 
as stability of the drugs [29]. Therefore, analogs which also contained 
fluorine were synthesized (compounds 6, 7 and 17; Fig. 2). 
The synthesis of the second-generation FLT3-Src inhibitors (Fig. 2) 
were accomplished following a Sonogashira protocol previously re-
ported by us, see SI [24]. With the compounds in hand, we evaluated 
their inhibitory activities against FLT3 and Src kinases at 500 nM con-
centrations using the Reaction Biology company kinase screening 
service (SI, Table S2). Compounds containing either monocyclic 
(aminopyridines) or bicyclic (amino isoquinoline or naphthyridine) 
moieties (in Fig. 2) potently inhibited (N90% inhibition of enzymatic 
activity at 500 nM) FLT3 and Src kinases. When the benzamide moiety 
in HSN286 (compound 8), HSN334 (compound 15) or HSN356 (Com-
pound 19) was replaced with a nicotinamide to give compounds 9, 16 
and 20, a significant increase (~1 log unit) in predicted aqueous solu-
bility was achieved (compare cLogP of compound 8 (5.7) with com-
pound 9 (4.4); compound 15 (4.9) with compound 16 (3.6) and 
compound 19 (4.0) with compound 20 (2.7)).  The  replacement  of  
the benzamide moiety in HSN286 with a nicotinamide moiety 
(9) did not affect FLT3 or Src inhibition. Compound 9 inhibited the 
proliferation of FLT3-ITD-harboring MV4–11 cells with a similar po-
tency to HSN286 (both compounds inhibited MV4–11 cells with 
IC50 value of ~0.5 nM). However, the replacement of the benzamide 
moiety in HSN286 with picolinamide moieties (HSN286 to 10 or 11), 
drastically affected the inhibition of FLT3 enzymatic activity (at 
500 nM, HSN286 inhibited FLT3 enzymatic activity by 97% whereas 
the picolinamide analogs, compounds 10 and 11 inhibited FLT3 at 
75% and 43% respectively, see Table S2). Therefore, we opted to 
make the nicotinamide derivatives HSN461 (compound 16), HSN459 
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Fig. 2. Alkynyl aminoisoquinoline and alkynyl naphthyridine compounds and other FLT3 inhibitors (midostaurin, quizartinib, crenolanib and ponatinib) evaluated in this study. 
To further probe the kinase inhibitory activity, we proceeded to de-
termine the IC50 values of the compounds against FLT3-ITD and Src. 
Since almost all the compounds had excellent FLT3 and Src inhibition 
(Table S2), we chose representative compounds for isoquinolines 
(HSN431) and naphthyridines (HSN459). HSN431 was equipotent 
against both kinases (12.5 nM against FLT3-ITD and 12.6 nM against 
Src kinase). HSN459 had an IC50 of 4.8 nM against FLT3-ITD and 
12.2 nM against Src (Fig. 3). 
4. Compounds inhibit AML cells harboring FLT3 TKD mutations 
Having established that the second-generation compounds were po-
tent inhibitors of MV4–11 cell proliferation (most compounds inhibited 
MV4–11 cells with IC50 b10 nM), we proceeded to evaluate the activities 
of the compounds against drug-resistant AML cell lines. As previously 
stated, the majority of FLT3 inhibitors provide initial response in the clinic 
but none p rovide complete cure due to t he emergence of resistancemech-
anisms. One of the major resistance mechanisms to FLT3 inhibitors is the 
emergence of a secondary mutation in the kinase domain [30,31]. Patients 
with double FLT3-ITD secondary TKD mutations have poorer prognosis 
than those with single FLT3-ITD or FLT3 TKD mutations. For example soraf-
enib, an FDA-approved drug for thyroid, liver and kidney cancers, potently 
binds to FLT3 and FLT3-ITD with Kd values of 13 nM and 95 nM respec-
tively and has shown activity against AML in the clinic [32]. But sorafenib 
is a poor binder of FLT3-ITD (D835V) or FLT3-ITD (F691 L) with Kd values 
of 630 nM and 860 nM respectively and resistance to sorafenib due to sec-
ondary mutations in FLT3 has been documented [18]. Midostaurin and 
newer generation FLT3 inhibitors, such as crenolanib, which are type I in-
hibitors fare better in binding to FLT3-ITD (F691 or D835) secondary mu-
tated kinases but as already mentioned midostaurin is not active as a single 
agent [11,12] and crenolanib suffers from pharmacokinetic issues [33] and  
requires multiple dosing regimens. The need for novel FLT3-targeted AML 
therapeutics that are active against the problematic secondary mutations 
can therefore not be overstated. Pleasingly, a handful of the compounds 
that showed excellent activities against FLT3-ITD-harboring MV4–11 
cells, also showed very good activity (using the MTT assay) against the 
drug-resistant MOLM-14 cell lines that harbored F691 L and D835Y sec-
ondary mutations. To confirm that the compounds were killing the AML 
cell lines, rather than just inhibiting growth, we used trypan blue exclusion 
assay to count viable cells after incubating MV4–11 with one model com-
pound, HSN431. The cell count indicated that viable MV4–11 cells de-
creased in presence of compound in dose-dependent manner (Fig. S1). 
4.1. Active compounds possess in vivo efficacy against MV4–11 cells 
Compounds HSN431, HSN459, 7, 11, 15, 20 and 26, inhibited MOLM-
14 (FLT3-ITD, D835Y) and MOLM-14 (FLT3-ITD, F691 L) with IC50 
values that are 15 nM or lower (see Fig. 4 and Table 1). HSN459, 
HSN431 as well as compounds 5, 9, 13, 18 and 24, were impressive as 
they were more active against MV4–11 cells and drug-resistant 
MOLM-14 cell lines than even the FDA-approved FLT3 inhibitor, 
midostaurin, or most FLT3 compounds in clinical trials (crenolanib, 
quizartinib and ponatinib, see Fig. 4 and Table 1). The ultimate goal of 
this study was to identify a preclinical compound that could be 
Fig. 3. In vitro kinase inhibition activity of select compounds. Inhibition of (a) FLT3-ITD (100 nM) and (b) Src (0.6 nM) by HSN431 and HSN459. IC50 values of each compound are shown in 
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translated into an AML therapeutic, so we proceeded to evaluate the 
compounds against MV4–11 cells in mice (Figs. 5–7 and S2–S5). 
The compounds that displayed potent activities against the AML cell 
lines in vitro (HSN286, HSN334, HSN352, HSN356, HSN431, HSN459, 
HSN461, HSN580, HSN581 and HSN620) were advanced for in vivo tol-
erability and efficacy studies on six-week-old NSG or NRG mice (see 
Figs. 5 & S2–S5). Female mice were dosed daily for 5 days via intraper-
itoneal injection and then monitored for an additional week for weight 
loss, a sign of toxicity in mice. It was found that when administered in-
traperitoneally, most of the compounds were tolerated at 25 mg/kg (no 
or transient weight loss b20% body weight). To evaluate the anti-
leukemic efficacy in vivo, six-week-old female NSG or NRG mice were 
injected intravenously with FLT3-ITD expressing acute myeloid leuke-
mia cells (MV4–11), expressing luciferase. Ten days after the initial 
MV4–11 injection, most of the mice showed some leukemia burden. 
Dosing (i.p) with the compounds was then started. The mice were 
dosed with 25 mg/kg of the compounds three times a week (MWF). 
Apart from HSN286, most of the tested compounds showed N99% reduc-
tion in leukemia burden after a few weeks (see Figs. 5 & S2–S5). 
HSN431, HSN580 and HSN459 were notable and it appeared that 
these compounds had cleared N99% of the leukemia in mice after few 
days. At 25 mg/Kg, the mice in the HSN459 group lost weight after 
one week so the dosing for this group was reduced to 10 mg/kg, 
which was tolerable (see Fig. S5). 
Since HSN431 could be dosed for several weeks without any adverse 
events and all five mice were still alive after day 73 (see Fig. 5; all the 
control mice had died by day 43), HSN431 was chosen as a model lead 
candidate and characterized further (Western analysis, cell cycle and 
apoptosis analysis). 
In the wildtype FLT3 signaling, activation of FLT3 occurs through bind-
ing to FLT3 ligand and subsequent phosphorylation of its TKD [34]. This 
causes the phosphorylation and activation of several downstream effector 
proteins via signaling pathways like the phosphatidylinositol-3-kinase 
(PI3K) - protein kinase B (Akt) and mitogen-activated protein kinase 
(MAPK) pathways [34]. These signaling pathways interact with each 
other and ultimately result in cell proliferation and survival [34]. Constitu-
tive activation of FLT3 through mutations leads to constitutively active 
downstream effectors and as such affords an enhanced cell survival and 
proliferation. We used Western blot analysis to investigate the effect of 
HSN431 on the phosphorylation of FLT3 and downstream effectors in 
FLT3-ITD expressing MV4–11 cells (Figs. 6 & S6). In agreement with our 
in vitro kinase results (Fig. 3 & Table S2), we observed an inhibition of 
the phosphorylation of FLT3 (Fig. 6). Inhibition of FLT3 phosphorylation 
was also observed in MOLM-14 (ITD, D835Y) cells (Fig. S7). In MV4–11 
cells, inhibition of the phosphorylation of Src was also observed 
(Fig. S8). Intriguingly, we found that after 48 h, the effect of HSN431 on 
Src phosphorylation was lower at 10 nM compared to 2 nM compound 
(Fig. S8). Although this was reproducible, the molecular basis is unclear 
and will be elucidated in future publications. We however, postulate 
that at higher concentrations, the compound could affect other pathways 
that modulate Src phosphorylation. Constitutive activation of Signal 
Transducer and Activator of Transcription 3 and 5 (STAT3 and STAT5) 
have been observed as a result of Src and FLT3 activation respectively 
[35,36]. Consistent with the inhibition of Src and FLT3 phosphorylation, 
STAT3 and STAT5 phosphorylation were inhibited (Figs. 6, S6 & S8). 
From the Western blot analysis, we also observed decreased phosphory-
lation of both Akt and ribosomal protein S6 kinase beta-1 (p70S6K) 
(Fig. S8), kinases in the PI3K-Akt-mTOR pathway that is activated in 
FLT3 signaling [34]. Phosphorylation and activation of Akt leads to the ac-
tivation of mammalian target of rapamycin (mTOR) which in turn acti-
vates p70S6K via phosphorylation [34]. Consequently, inhibition of Akt 
phosphorylation would lead to decreased phosphorylation of p70S6K as 
observed (Fig. S8). The activation of p70S6K leads to increased protein 
translation, which is important for cell survival [34,37,38]. Interestingly, 
from cell-free in vitro kinase assays, we found that HSN431 inhibited the 
kinase activity of p70S6K with an IC50 of 44.7 nM but not the upstream 
kinases PI3K, Akt and mTOR (Fig. 7). Hence inhibition of FLT3 kinase activ-
ity (Fig. 3) may be responsible for the observed decrease in Akt and 
p70S6K phosphorylation. 
The mitogen-activated protein kinase (MAPK) pathway has been 
demonstrated to be involved in leukemogenesis due to the activation 
of the Ras-Raf-MEK-extracellular signal-regulated kinase (ERK) cas-
cade [39]. Down-regulation of this cascade results in cell cycle arrest 
and induces apoptosis [40,41]. Others have shown that the phosphor-
ylation of p38 MAPK was enhanced in MV4–11 cells and p38 activity 
has been implicated in leukemogenesis [42,43]. We observed inhibi-
tion of the phosphorylation of ERK, p38 and a modest inhibition of 
c-Myc which is downstream of p38 by HSN431 (Fig. S8). For inhibition 
of ERK phosphorylation, we found that HSN431 appeared to inhibit 
ERK phosphorylation better after 6 h than after 48 h (Fig. S8). Time-
dependent increase in ERK phosphorylation following initial decrease 
has been observed by others in MV4–11 and MOLM-14 cell lines 
[44]. Further analysis by kinase inhibition assays revealed that 
HSN431 inhibited the kinase activity of A-Raf (IC50 = 27.6 nM), B-
Raf (IC50 = 26.3 nM) and Raf-1 or c-Raf (IC50 = 12.8 nM) but not 
the downstream effectors MEK1, ERK1 and RSK1 (Fig. 7). The observa-
tion that HSN431 inhibits the Raf kinase activity, which is required for 
the activation of ERK, potentially explains the observed decrease in 
cellular ERK phosphorylation. 
4.2. HSN431 induces G1 cell cycle arrest and apoptosis 
The effect of HSN431 on cell cycle in the AML cell lines was evaluated. 
From the cell cycle analysis, an increase in the population of cells in the 
G0/G1 phase was observed when the AML cell lines tested were treated 
with HSN431. The accumulation of G0/G1 phase cells was observed to be 
Fig. 4. Anti-proliferative activity of second-generation compounds. The IC50 values against MV4–11 (black), MOLM-14 (red), MOLM-14 (ITD, D835Y) (blue) and MOLM-14 (ITD, F691 L) 
(green) cells were plotted for each compound. Compounds with 15 nM or less IC50 against all 4 cell lines are marked with *. Each bar represents the average of triplicates plotted using 
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Table 1 
Summary of anti-proliferative activities of select compounds. 
Compounds IC50 (mean ±SD, nM) 
















13 0.4±0.006 1.4± 0.03 4.7±0.03 1.1±0.04 






















Ponatinib 0.1±0.001 0.5± 0.1 52.6±0.3 6.8±0.03 
both dose- and time-dependent. Also, corresponding decreases in the 
distribution of cells in the S phase (Figs. 8 and S9) were observed. A gen-
eral decrease in the distribution of cells in the G2 phase was also ob-
served. Additionally, we also observed an accumulation of cells in the 
sub-G1 phase across the tested AML cell lines. A further analysis of the 
antileukemic effect of HSN431 revealed that the compound induced ap-
optosis in the AML cell lines. Again, we observed both dose- and time-
dependent increases in total apoptosis (Figs. 9 and S10). 
5. Discussion 
Several reports have documented that the inhibition of FLT3 [1,45] 
or Src kinase [46] is an attractive strategy to inhibit the proliferation of 
AML. Whereas FLT3 plays a key role in leukemogenesis in about 30% 
of AML patients [6,7], Src-family kinases, which are downstream of 
FLT3, are over-expressed in AML and collaborate with FLT3 to facilitate 
AML progression [46]. In addition to Src, HCK and Lyn (both are Src ki-
nase family members) are inhibited by the reported aminoisoquinolines 
[24]. HCK is known to be expressed in human primary leukemic stem 
cells and not as much in human normal hematopoietic stem cells. Lyn 
is known to play a key role in the progression of AML [47]. Indeed 
dasatinib, a Src-family inhibitor, which is an FDA approved drug for 
CML has been shown to be effective against AML [46]. We had earlier 
reported that aminoisoquinoline benzamides are dual FLT3-Src-family 
kinase inhibitors with potent activities against FLT3-ITD harboring 
AML cell lines MV4–11 and MOLM-14 [24]. The first-generation com-
pounds (such as HSN286, HSN334 and HSN356) (Fig. 1) were however 
not drug-like (high LogP values for example) and were poorly active 
Fig. 5. Evaluation of the in vivo efficacy of HSN431. (a) Structure HSN431. (b) The effect of HSN431 (25 mg/kg IP; 3×/week) treatment on mice (n = 5) implanted with FLT3-ITD harboring 
MV4–11 cells. (c) Table of photon intensity on whole body values for images shown in (b). (d) Quantification of leukemia burden in mice by measuring photon intensity (emanating from 
bioluminescent MV4–11 cells) on whole body of different treatment groups (control versus HSN431) over time. (e) Body weight measurements of control versus HSN431 treatment. 
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Fig. 6. Evaluation of the effect of HSN431 on protein phosphorylation in MV4–11 cells. Cells were treated with 2 nM or 10 nM HSN431 for 6 h and 48 h and protein extracts were probed 
with primary antibodies of (a) phospho-FLT3, FLT3 phospho-STAT5 and STAT5 and (b) phospho-STAT3 and STAT3. Primary antibodies of indicated kinases or proteins were detected using 
anti-rabbit or anti-mouse secondary antibodies. Scanned images were analyzed using image J software. For full immunoblots, see Fig. S6. 
against AML with secondary FLT3 mutations. However, the second-
generation alkynyl aminoisoquinoline and alkynyl aminonaphthyridine 
compounds (Fig. 2) had reduced LogP values and possessed potent ac-
tivity against AML cell lines harboring secondary FLT3 mutations 
(Fig. 4). 
AML patients who harbor FLT3-ITD mutations have worst prognosis 
[48]. Most FLT3 TKIs in clinical trials including crenolanib, quizartinib 
and gilteritinib as well as midostaurin, the first FDA approved FLT3 
TKI, are effective against FLT3-ITD mutations [11,33,49,50]. It has 
emerged that, the activation loop mutation D835Y/V as well as the gate-
keeper mutation F691 L contribute significantly to resistance to FLT3 
TKIs, consequently leading to AML relapse [18,25,51]. The ability of a 
FLT3 TKI to inhibit these mutant forms could translate into better clini-
cal outcomes. HSN431, HSN459, and compound 24 among others, ex-
hibited similar or better anti-leukemic activity against drug-resistant 
AML cells including MOLM-14 cells harboring double FLT3-ITD-D835Y 
and FLT3-ITD-F691 L mutations compared to midostaurin, crenolanib, 
quizartinib and ponatinib. 
In an in vivo mouse xenograft model, using MV4–11 model that was 
previously used to evaluate crenolanib [33], HSN431 at 25 mg/kg and 
dosed three times per week drastically reduced the whole-body photon 
count due to the bioluminescence of MV4–11-luc cells, compared to 
control. Furthermore, HSN431 treatment improved mice survival. By 
day 40, all the control mice had died whereas 100% of HSN431-treated 
mice were still alive (Fig. 5). 
HSN431 is a multitargeted kinase inhibitor and it is likely that the 
potent activity in vivo against AML is due to the ability to not only inhibit 
FLT3 but some of the downstream targets. In fact, most kinase inhibitors, 
including even ones that the investigators claimed were selective 
agents, have now been shown to target multiple targets [52]. Plausibly 
the clinical successes of the many FDA-approved TKIs, which are 
multitargeting kinase inhibitors, derive from their ability to inhibit the 
signaling pathway that lead to tumor/cancer growth (i.e. cancer driver 
kinase and downstream “collaborating” kinases) as well as kinases 
that regulate the tumor microenvironment [53] and/or immunokinases, 
which either activate cytotoxic T-cells and/or inhibit suppressor im-
mune cells [54]. A limitation of multitargeting kinase inhibitors is the 
issue of dose-limiting toxicities, due to the inhibition of kinases that 
are also essential for normal physiological function. Irrespective of 
mode(s) of action, increasing survival of patients whiles not drastically 
impacting quality of life (due to adverse events) should be the main 
criteria for a drug selection. In this regard, we believe that HSN431 has 
a potential to be translated in the clinic since it could be dosed to mice 
for several weeks without any obvious signs of toxicity, such as weight 
loss or animal discomfort, and importantly drastically improved sur-
vival of mice injected with AML cells (Fig. 5). 
In summary, we have developed alkynyl aminoisoquinoline and 
alkynyl naphthyridine compounds with potent in vitro FLT3-Src kinase 
inhibition. The compounds demonstrated potent activities against TKI-
resistant FLT3-ITD cell lines and were efficacious in in vivo mouse AML 
studies. HSN431 and analogs thereof could be developed further as 
anti-AML compounds. 
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Fig. 7. In vitro kinase inhibition by HSN431. The dose-response curves obtained by incubating increasing concentrations of HSN431 with kinases in the (a) PI3K/AKT/mTOR pathway and 
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Fig. 8. The effect of HSN431 on cell cycle distribution. DMSO (vehicle) or HSN431 at the indicated concentrations was incubated with (a) MV4–11, (b) MOLM-14, (c) MOLM-14 (ITD, 
D835Y) and (d) MOLM-14 (ITD, F691 L) cells for 24 h and 48 h. Cells were harvested by centrifugation, washed, fixed in 70% ethanol and stained with propidium iodide (PI) before 
being analyzed by flow cytometry. For each stacked bar, the distribution of cells in the G1 phase (blue), S phase (red), G2 phase (green) and sub-G1 (magenta) have been indicated by 
their percentages. Samples were analyzed in triplicates on a FACSCanto II flow cytometer (BD Bioscience, San Jose, CA, USA) and data were analyzed with FlowJo software (Flowjo, LLC, 
Ashland, OR, USA). Data represent the mean ± SD of triplicate measurements. 
Fig. 9. HSN431 induces apoptosis in AML cells. Flow cytometry analysis of the total apoptosis of (a) MV4–11, (b) MOLM-14, c) MOLM-14(ITD, D835Y) and d) MOLM-14 (ITD, F691 L) cells 
treated with DMSO (vehicle) or the indicated concentrations of HSN431 for 24 and 48 h. At the indicated time-points, cells were harvested, washed and stained with FITC Annexin V and PI 
and analyzed by flow cytometry on a FACSCanto II flow cytometer. Total apoptosis (%) was defined as the sum of percentages of early and late apoptotic cells. Experiment was performed in 
triplicates and presented as mean ± SD. 
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